STLN logo

STARLING ONCOLOGY INC

STLNNASDAQ
🏆 #2780 by market capUS Equity
$6.51▼ $0.13 (−1.96%)
🌙 After hours$6.53▲ 0.31%Regular close · extended-hours price shown
🔔
Track STLN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.0%
7d▼ 4.7%
14d▼ 0.4%
30d▲ 10.2%
ytd▲ 83.4%
1y▲ 85.7%
🏦Market Cap
$651M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
15.7%
Thin
💵FCF Margin
-0.6%
Thin
⚖️P/S Ratio
1.1x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$6.47 – $6.56
52-Week Range
$2.32 – $7.13
Volume
$2.98B
Avg Volume
$2.03B
Shares Outstanding
100.0M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$503M
Last Q Revenue
$161M
P/E Ratio
-21.7
P/S Ratio
1.1x
EPS (TTM)
$-0.35
Dividend Yield
0.00%

Why Investors Own STLN

  • ✓High-growth profile — revenue up +15.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 51% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STLN logo

STARLING ONCOLOGY INC

STLN
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$503M▲ +10.1% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
50.8%▲ +2.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$140M▲ +10.1% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$68M▲ +10.1% YoY
StockOtter · stockotter.space

About STARLING ONCOLOGY INC

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$8.50
▲ +30.6% Upside
High Target$10.00
Low Target$7.14
Based on 24 analysts

Latest News & Updates

GlobeNewsWire·Aug 24

Starling Oncology to Participate in Wells Fargo Healthcare Conference

CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that

GlobeNewsWire·Aug 17

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the la

Seeking Alpha·Aug 7

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Zacks Investment Research·Aug 6

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.

GlobeNewsWire·Aug 6

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financia